Dillon & Associates Inc. lifted its position in Amgen Inc. (NASDAQ:AMGN – Get Rating) by 4.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,924 shares of the medical research company’s stock after acquiring an additional 120 shares during the period. Dillon & Associates Inc.’s holdings in Amgen were worth $658,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of AMGN. Dixon Hughes Goodman Wealth Advisors LLC acquired a new position in shares of Amgen during the 4th quarter worth $26,000. Norwood Financial Corp bought a new stake in shares of Amgen in the 4th quarter worth approximately $28,000. Industrial Alliance Investment Management Inc. acquired a new stake in shares of Amgen during the 4th quarter valued at about $31,000. Econ Financial Services Corp bought a new position in Amgen in the 4th quarter valued at $34,000. Finally, PYA Waltman Capital LLC bought a new position in Amgen in the fourth quarter valued at about $34,000. 79.01% of the stock is currently owned by hedge funds and other institutional investors.
AMGN has been the topic of a number of research reports. BMO Capital Markets cut their price objective on shares of Amgen from $263.00 to $243.00 in a research report on Thursday, April 28th. TheStreet cut Amgen from a “b+” rating to a “c+” rating in a report on Wednesday, April 27th. StockNews.com raised Amgen from a “buy” rating to a “strong-buy” rating in a research note on Monday, May 16th. Morgan Stanley cut their price objective on Amgen from $238.00 to $237.00 and set an “equal weight” rating on the stock in a research note on Tuesday, April 12th. Finally, Barclays increased their price objective on shares of Amgen from $233.00 to $236.00 and gave the stock an “equal weight” rating in a research report on Tuesday, April 12th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Amgen currently has an average rating of “Hold” and a consensus target price of $243.07.
Amgen (NASDAQ:AMGN – Get Rating) last released its quarterly earnings results on Wednesday, April 27th. The medical research company reported $4.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.22 by $0.03. Amgen had a return on equity of 165.95% and a net margin of 21.75%. The firm had revenue of $6.24 billion for the quarter, compared to analyst estimates of $6.09 billion. During the same quarter last year, the company posted $3.70 earnings per share. As a group, research analysts expect that Amgen Inc. will post 17.48 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 8th. Investors of record on Tuesday, May 17th will be given a $1.94 dividend. The ex-dividend date is Monday, May 16th. This represents a $7.76 annualized dividend and a dividend yield of 3.07%. Amgen’s dividend payout ratio is presently 76.38%.
In other news, Director R Sanders Williams sold 600 shares of Amgen stock in a transaction dated Monday, May 23rd. The stock was sold at an average price of $250.00, for a total value of $150,000.00. Following the transaction, the director now directly owns 5,501 shares of the company’s stock, valued at approximately $1,375,250. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jonathan P. Graham sold 13,500 shares of the company’s stock in a transaction on Tuesday, May 10th. The stock was sold at an average price of $241.81, for a total transaction of $3,264,435.00. Following the sale, the executive vice president now directly owns 37,333 shares of the company’s stock, valued at $9,027,492.73. The disclosure for this sale can be found here. 0.46% of the stock is owned by corporate insiders.
Amgen Profile (Get Rating)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
- Get a free copy of the StockNews.com research report on Amgen (AMGN)
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
- Is RBC Bearings Rolling Into A Reversal?
- Should Dollar General or Dollar Tree Give Investors a Case of FOMO?
- Genesco Pops On Earnings But Don’t Expect A Rally
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.